The peculiar thing about a prescription is that having insurance does not always settle the price. SingleCare’s own instructions tell insured customers to compare its discount with their copay. Sometimes the card wins. The medicine is the same; the route by which you pay for it has changed. A pharmacy counter, it turns out, can conceal a rather elaborate switching yard.
- For consumers: SingleCare offers free coupons for participating pharmacies.
- For benefit teams: RxIQ provides claims processing, configuration, analytics and pricing tools.
- For pharmacies: branded marketplaces compare selected discount programs.
- The interesting bet: better access to the machinery can change who controls the benefit.
RxSense is the Boston company working on several tracks at once. Most people who encounter its consumer brand will never need to know what claims adjudication means. Its business customers very much do. Behind the cheerful coupon sits software deciding how a prescription transaction should be handled, what a plan permits and which price applies.
That combination gives the company an unusual position. It can help a shopper find a discount, sell infrastructure to a pharmacy benefit manager, and help a health system administer a benefit more directly. The company’s subject is affordability. Its instrument is control over the transaction.
The copay has company
Start with the ordinary customer. SingleCare is free to use, works through participating pharmacies, and is a discount service rather than insurance. A customer searches for the prescription, compares pharmacy prices, and presents the coupon. The practical details matter: strength, quantity and the prescribed product must match. A price attached to the wrong prescription is an attractive answer to the wrong question.
SingleCare says it negotiates directly with pharmacies and receives a small fee from pharmacy partners when a card is used. This explains the apparent generosity without requiring a fairy godmother. The consumer gets access to the negotiated price; the pharmacy pays for a transaction brought through the service. “Free” describes the customer’s cost of using the card.
The distinction becomes more interesting inside a benefit. RxIQ Autosave compares a member’s benefit price with selected discount cards. RxSense says the integrated product applies the lowest available price to the member’s deductible. That is a different arrangement from handing a pharmacist a standalone coupon. Here, the comparison is part of the benefit workflow, rather than an extra errand performed by the patient.
The word “selected” deserves attention. A comparison engine can only choose among the options connected to it. Walgreens’ Rx Savings Finder, powered by RxSense, searches discount-card prices for eligible prescriptions filled at Walgreens. Its instructions say prices vary and can change. The sensible attraction is a convenient comparison within that setting; the tool does not survey every imaginable way to buy a medicine.
A coupon company with an engine room
Rick Bates founded RxSense in 2015 after a career in healthcare that included serving as president and chief operating officer of Catalyst Health Solutions. The founding premise was grounded in experience with older pharmacy-benefit systems. He assembled healthcare veterans and technologists to build a different platform. In May 2020, Parthenon Capital announced an investment, with proceeds intended for growth initiatives and financial terms undisclosed.
The enterprise business is sold to organizations: PBMs, health plans, health systems, third-party administrators and large employers. Earlier public materials called the platform RxAgile. Today, the product family is presented under RxIQ. The naming is less revealing than the jobs the tools perform.
Configure benefits and process claims.
Examine claims, trends and alerts.
Optimize pricing within contract rules.
RxIQ Enterprise handles claims adjudication, benefit hierarchies and formulary configuration. A formulary is the plan’s drug list; configuration determines how that list and the benefit’s rules become an actual transaction. The appeal to an administrator is direct access to those settings. A policy decision becomes more useful when the people responsible for it can put it into operation.
Business Intelligence adds dashboards, custom alerts and repricing using historical claims and pricing inputs. It is aimed at a familiar administrative irritation: receiving useful information after the moment when it would have been most useful. The product is designed to let teams inspect claims and test financial consequences sooner.
Price AI deals with contract rules, exclusions and performance guarantees. Users set limits for adjustments; the system monitors results and optimizes pricing within those boundaries. The valuable question for a buyer is quite concrete: which rules are represented, which targets are being pursued, and who has authority to change them?
RxSense offers core, modular and full-service relationships. A buyer can purchase technology, combine tools with existing vendors, or obtain broader operational support. This is an important part of its competitive position. Organizations differ in how much of the pharmacy-benefit operation they want to own. Selling several levels of support makes that choice less binary.
The hospital that moved the prescriptions
One RxSense case study concerns an unnamed health system covering 65,000 employees and dependents. It wanted to operate its own PBM and make more use of its internal pharmacies. With RxIQ Enterprise and support from RxSense, the company says the system launched the PBM within months.
The published result is worth looking at operationally. The share of claims filled in-house rose from 18% to 41%. The system also used internal specialty pharmacies, direct rebate-management contracting and RxSense’s network support. The case study reports $7 million in annualized savings in year one.
This is a case study supplied by the vendor, not a promise for the next hospital. Its logic depends on assets and arrangements that existed in this particular organization, including dispensing capacity and purchasing strategies. A system without comparable pharmacy resources would be attempting a different project. The saving is interesting precisely because it arose from changing how an existing operation was used.
There is a useful lesson here for buyers of enterprise software. Ask what behavior changes after installation. In this case, more prescriptions moved into internal dispensing channels. That is a clearer explanation of value than a list of dashboard features. It also helps a buyer identify the work involved: contracts, operating decisions, implementation and the ability to serve the patients whose prescriptions move.
ProAct offers a named customer example. In a video published by RxSense in January 2026, chief operating officer Deb Dempsey discusses simpler benefit configuration and real-time access to claims and reporting. The theme is mundane in the best sense: fewer manual steps, more visibility, quicker decisions. Administrative products earn their keep in such details.
Eight weeks outside the usual room
RxSense’s own analytics work supplied a revealing complication. In a June 2025 Wharton account, Bates described stalled progress on benefit-plan construction and long-range drug-pricing projections. “We were stuck,” he said. Two student teams spent eight weeks on the problems, with weekly company check-ins, and introduced modeling approaches the internal team had not considered.
“We were stuck.”
Rick Bates, describing the analytics roadblock to Wharton
The reported outcome was new frameworks and next steps toward automation. The lesson is an inference from the process: give outsiders a bounded problem, access to relevant data and regular contact with the people who understand its consequences. The company’s experts remained involved. Fresh eyes were useful because they had something specific to examine.
The next price to find
On August 4, 2026, RxSense announced a TailorMed partnership to bring manufacturer copay and foundation assistance information into participating digital pharmacy marketplaces. The integration covers programs for more than 2,200 brand-name medications. That expands the menu of possible help beyond comparing discount cards. Eligibility still matters: displaying an assistance program is the beginning of finding out whether someone can use it.
For pharmacies, RxSense also offers GlobalBIN, where staff enter a single Plan ID to reach a discount price chosen through configured logic. Its marketplaces let the pharmacy choose participating cards and branding. For consumers, the visible task remains short: find a prescription, see the available prices, use the appropriate option. Much of the enterprise work exists to make that short task possible.
RxSense’s place in the market is consequently broader than a coupon brand. Consumer alternatives include other prescription-discount services; enterprise buyers compare administration technology and service arrangements. Its distinctive proposition is to connect pricing, claims and operational choice across those audiences. The small act at the counter makes more sense once you see the larger system behind it. A price can look inevitable until somebody builds a way to compare it.